Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.70 |
| ▸ | HTR2A | P28223 | 5/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491776 | 0.92 | MCHR1 (0.70) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL4481899 | 0.89 | MCHR1 (0.64) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL4469433 | 0.88 | MCHR1 (0.62) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL2328706 | 0.87 | MCHR1 (0.76) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL4476476 | 0.86 | MCHR1 (0.72) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL4486685 | 0.86 | MCHR1 (0.73) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL4488570 | 0.85 | MCHR1 (0.70) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL4478722 | 0.85 | MCHR1 (0.73) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL13708515 | 0.84 | MCHR1 (0.69) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 | |
| SCHEMBL4472111 | 0.84 | MCHR1 (0.69) | MCHR1CHRM1HTR2ACYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592358-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | claimed |
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| US-7592358-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592358-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592358-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MCHR1 1/4885CHRM1 125/4885HTR2A 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.